drugset / Trial / NCT06268093

The Therapeutic Effect of Thalidomide in Syringomyelia

NCT06268093

Phase 2 Recruiting 30 enrolled Xuanwu Hospital, Beijing
NaSingle-groupOpen-labelTreatment

Summary

Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.

Timeline

Start
2024-02
Primary completion
2027-02
Completion
2028-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 50 mg Oral
Subject Thalidomide Other / unclassified 200 mg Oral